Allogene Therapeutics
ALLO
154 hedge funds and large institutions have $413M invested in Allogene Therapeutics in 2023 Q3 according to their latest regulatory filings, with 13 funds opening new positions, 67 increasing their positions, 37 reducing their positions, and 29 closing their positions.
81% more repeat investments, than reductions
Existing positions increased: 67 | Existing positions reduced: 37
0% more funds holding in top 10
Funds holding in top 10: 2 → 2 (0)
10% less funds holding
Funds holding: 171 → 154 (-17)
13.74% less ownership
Funds ownership: 91.47% → 77.73% (-14%)
38% less capital invested
Capital invested by funds: $663M → $413M (-$250M)
55% less first-time investments, than exits
New positions opened: 13 | Existing positions closed: 29
58% less call options, than puts
Call options by funds: $195K | Put options by funds: $469K
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Vanguard Group
Malvern,
Pennsylvania
|
+$13.5M |
| 2 |
JP Morgan Chase
New York
|
+$3.4M |
| 3 |
Dimensional Fund Advisors
Austin,
Texas
|
+$2.39M |
| 4 |
BlackRock
New York
|
+$1.96M |
| 5 |
CANY
Caxton Associates (New York)
New York
|
+$1.8M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
T. Rowe Price Associates
Baltimore,
Maryland
|
-$12.8M |
| 2 |
BBA
Baker Bros. Advisors
New York
|
-$7.84M |
| 3 |
Cerity Partners
New York
|
-$2.97M |
| 4 |
Two Sigma Investments
New York
|
-$2.86M |
| 5 |
Citadel Advisors
Miami,
Florida
|
-$2.74M |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
BC
176
Bridgefront Capital
Austin,
Texas
| – | -$53.6K | -10,781 | Closed |
|
177
Simplex Trading
Chicago,
Illinois
| – | -$34.3K | -7,821 | Closed |
|
178
Point72 Asset Management
Stamford,
Connecticut
| – | -$11K | -2,217 | Closed |
|
179
Federated Hermes
Pittsburgh,
Pennsylvania
| – | -$845 | -170 | Closed |
|
|
C
180
Covestor
London,
United Kingdom
| – | -$13 | -3 | -12% |
|
|
NS
181
NBC Securities
Birmingham,
Alabama
| – | +$876 | +200 | New |
|
ALLO Hedge Fund Activity: Q3 2023 in Review
154 of the 6,301 institutional investors tracked by Wall St. Rank reported a position in Allogene Therapeutics (ALLO) for Q3 2023, worth a combined $413M — down 38% from $663M a quarter earlier.
Sellers outnumbered buyers: 29 funds closed out of ALLO and 13 opened new positions — a net loss of 16 holders — while 37 trimmed existing stakes and 67 added.
The largest buyer was Vanguard Group, adding an estimated $13.5M. The largest seller was T. Rowe Price Associates, cutting an estimated $12.8M.
- 154 institutional investors held Allogene Therapeutics (ALLO) as of Q3 2023, down from 171 in Q2 2023.
- Funds reported $413M of Allogene Therapeutics stock for Q3 2023, down 38% quarter-over-quarter.
- 13 funds opened new Allogene Therapeutics positions in Q3 2023 and 29 closed out, a net change of -16 holders.
- The largest Allogene Therapeutics buyer in Q3 2023 was Vanguard Group, an estimated $13.5M added.
- The largest Allogene Therapeutics seller in Q3 2023 was T. Rowe Price Associates, an estimated $12.8M sold.
Based on aggregated 13F filings for Q3 2023.